Within this study, the addition of Palbociclib to Letrozole in patients with advanced, ER-positive and HER2-negative BC demonstrated a prolongation of PFS of ten months (20.2 months vs. 10.2 months, hazard ratio (HR) 0.49, p = 0.0004) [17]. Here, ERBB2 is linked to breast cancer.